References
- Serruys PW, de Jaegere P, Kiemeneji F et al A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benstent Study Group. N Engl j Med 331,489–495 (1994).
- Macaya C, Serruys PW, Ruygrok P et al Continued benefit of coronary stenting versus balloon angioplasty: 1-year clinical follow-up of Benestent trial. Benestent Study Group. J. Am. Coll Cardiol 27,255–262 (1996).
- Kiemeneij F, Serruys PW, Macaya C et al Continued benefit of coronary stenting versus balloon angioplasty: 5-year clinical follow-up of Besestent-I trial. J. Am. Coll Cardiol 37, 1598–1603 (2001).
- Fischman DL, Leon MB, Baim DS et al A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl Med 331,496–501(1994).
- Savage MB Fischman L, Rake R et al Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. STent REStenosis Study (STRESS) Investigators. J. Am. Coll Cardiol 31,307–311 (1998).
- Elezi S, Kastrati A, Pache J et al Diabetes mellitus and the clinical and angiographicoutcomes after coronary stent placement. J. Am. Coll Cardid 32,1866–1873 (1998).
- Elezi S, Kastrati A, Neumann FJ et al Vessel size and long-term outcome after coronary stent placement. Circulation 98,1875–1880 (1998).
- Kastrati A, Elezi S, Dirchinger J et al Influence of lesion length on restenosis after coronary artery replacement. Am. j Cardiol 83,651–659 (1999).
- Kobayashi Y, de Gregorio J, Kobayashi N et al Stented segment length as an independent predictor of restenosis. j Am. Coll Cardid 34,651–659 (1999).
- Sollott SJ, Cheng L, Pauly RR et al Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.Clin. Invest. 95,1869–1876 (1995).
- Rowinsky EK, Donehower RC. Paclitaxel (taxon. N Engl j Med. 332,1004–1014 (1995).
- Axel DI, Kunert W Göggellmann C et al Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96,636–645 (1997).
- Baumbach A, Herdeg C, Kluge M et al Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter Cardiovasc. Interv. 47,103–106 (1999).
- Oberhoff M, Kunert W, Herdeg C et al Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res. Cardid 96,275–282 (2001).
- Oberhoff M, Herdeg C, Al Ghobainy R et al Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc. Interv. 53,562–568 (2001).
- Heldman AW, Cheng L, Jenkins M et al Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103, 2289–2295 (2001).
- Van der Giessen WJ, Lincoff AM, Schwartz RS et al Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94,1690–1697 (1996).
- Farb A, Heller PF, Shroff S et al Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104, 473–479 (2001).
- Drachman DE, Edelman ER, Seifert P et al Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over 6 months. J. Am. Coll Cardiol. 36, 2325–2332 (2000).
- Finkelstein A, McClean D, Kar S et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107, 777–784 (2003).
- Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J. Am. Coll. Cardiol 42, 1415–1420 (2003).
- Honda Y, Grube E, de la Fuente LM et al. Novel drug-delivery stent: intravascular ultasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 104, 380–383 (2001).
- Virmani R, Liistro F, Stankovic G et al. Mechanism of late in-stent restenosis after implantation of paclitaxel derivate-eluting polymer stent system in humans. Circulation 106, 2649–2651 (2002).
- Drachman DE. Clinical experience with drug-eluting stents. Rev. Cardiovasc. Med. 3\(Suppl. 5), S31—S37 (2002).
- Kataoka T, Grube E, Honda Y et al. 7-Hexanoxyl-eluting stent for the prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106, 1788–1793 (2002).
- Liistro F, Stankovic G, Di Mario C et al. First clinical experience with a paclitaxel derivative-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105, 1883–1886 (2002).
- Grube E, Silber S, Hauptmann KE et al. TAXUS I 6- and 12-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107, 38–42 (2003).
- •Initial feasibility and safety trial of paclitaxel stents establishing safety.
- Bullesfeld L, Gerckens U, Muller R, Grube E. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18-month follow-up of TAXUS I. Z Kardiol 92, 825–832 (2003).
- Colombo A, Drzewiecki J, Banning A et al Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108, 788–794 (2003).
- •Trial establishing the efficacy of paclitaxel stents in preventing restenosis in a large population.
- Tanabe K, Serruys PW, Degertekin M et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 109, 196–200 (2004).
- Serruys PW, Degertekin M, Tanabe K et al. Vascular responses at proximal and distal edges of paclitaxel stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 109, 627–633 (2004).
- Stone GW, Ellis SG, Cox DA et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl. J. Med 350, 221–231 (2004).
- Stone GW, Ellis SG, Cox DA et al. 1-year clinical results with the slow-release, polymer-based paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109(16), 1942–1947 (2004).
- Tanabe K, Serruys PW, Grube E et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107, 559–564 (2003).
- •Feasibility and safety trial showing that paclitaxel stents are safe in in-stent restenosis.
- Park S-J, Shim WH, Ho DS et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J. Med 348, 1537–1545 (2003).
- Hong M-K, Mintz GS, Lee CW et al Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular analysis from the ASian Paclitaxel-Eluting stent Clinical Trial (ASPECT). Circulation 107, 517–520 (2003).
- Gershlick A, De Scheerder I, Chevalier B et al Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109, 487–493 (2004).
- Lansky AJ, Costa RA, Mintz GS et al Nonpolymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Angiographic follow-up of the DELIVER clinical trial. Circulation 109(16), 1948–1954 (2004).
- Morice M-C, Serruys PW, Sousa JE et al A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346, 1773–1780 (2002).
- Moses JW, Leon MB, Popma JJ et al Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349, 1315–1323 (2004).
Websites
- MSN money news.moneycentral.msn.comhicker/sigdev.as p?Symbol=BSX&Page Num=3 (Accessed August 2004)
- DELIVER trial results www.hartziekten.nlicardio.nl/ACC2003/AC CIS-LBCT-II/DELIVERhtnal (Accessed August 2004)
- •News of the trial showing that long-term benefits are not apparent when paclitaxel is used without a polymer.